Evidence mapPaperPMID 41877181Full record

ReviewBMC medicine2026

The need for clinical studies assessing whether weight loss improves functional outcome after stroke in diabetes.

Ellen Vercalsteren, Michael V Mazya, Thomas Nyström, Vladimer Darsalia, Cesare Patrone

Abstract readReview
In one paragraph

Review in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ellen VercalsterenNeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, 118 83, Sweden.ORCID 0000-0002-9425-4209
Michael V MazyaDepartment of Neurology, Department of Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, 171 76, Sweden.ORCID 0000-0002-0377-3506
Thomas NyströmNeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, 118 83, Sweden.ORCID 0000-0002-3462-7990
Vladimer DarsaliaNeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, 118 83, Sweden.ORCID 0000-0002-6693-934X
Cesare PatroneNeuroCardioMetabol Group, Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, 118 83, Sweden. cesare.patrone@ki.se.ORCID 0000-0003-0470-4606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 2 diabetes worsens functional outcome after stroke, severely affecting the rehabilitation processes, with no therapy available for this medical problem. MAIN TEXT: Weight loss is an effective strategy for managing type 2 diabetes, with some studies also showing that it can reduce cardiovascular and stroke risk in this population. Recent animal studies suggest that weight loss induced by a diet change or pharmacologically (via the activation of the glucagon-like peptide 1 receptor) also improves functional outcome after stroke. Today, however, no clinical study has yet addressed this question. This issue is important to address since type 2 diabetes is one of the strongest risk factors for stroke and the growing prevalence of diabetes is leading to an increasing number of stroke patients with type 2 diabetes who will require effective therapies. Here, we discuss recent findings showing the positive effects of weight loss in type 2 diabetes and its cardiovascular complications, underlining the need to perform new clinical studies specifically focused on understanding the potential therapeutic role of weight loss to improve functional outcomes after stroke.

conclusionsIn summary, this debate underscores a critical clinical gap in current post-stroke care strategies and highlights the potential for weight loss as a novel treatment paradigm to improve functional stroke outcomes in type 2 diabetes. If validated in clinical studies, this approach will significantly improve the quality of life of many stroke patients with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2StrokeWeight LossAnimalsHumansTreatment OutcomeDiabetesGlucagon-like peptide 1 receptor agonistsObesityStrokeWeight loss

Identifiers

PMID41877181
PMCPMC13064103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.